5822. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial.
作者: Sanjiv J Shah.;Barry A Borlaug.;Eugene S Chung.;Donald E Cutlip.;Philippe Debonnaire.;Peter S Fail.;Qi Gao.;Gerd Hasenfuß.;Rami Kahwash.;David M Kaye.;Sheldon E Litwin.;Philipp Lurz.;Joseph M Massaro.;Rajeev C Mohan.;Mark J Ricciardi.;Scott D Solomon.;Aaron L Sverdlov.;Vijendra Swarup.;Dirk J van Veldhuisen.;Sebastian Winkler.;Martin B Leon.; .
来源: Lancet. 2022年399卷10330期1130-1140页
Placement of an interatrial shunt device reduces pulmonary capillary wedge pressure during exercise in patients with heart failure and preserved or mildly reduced ejection fraction. We aimed to investigate whether an interatrial shunt can reduce heart failure events or improve health status in these patients.
5823. Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021.
National rates of COVID-19 infection and fatality have varied dramatically since the onset of the pandemic. Understanding the conditions associated with this cross-country variation is essential to guiding investment in more effective preparedness and response for future pandemics.
5826. Report of the Lancet Commission on the Value of Death: bringing death back into life.
作者: Libby Sallnow.;Richard Smith.;Sam H Ahmedzai.;Afsan Bhadelia.;Charlotte Chamberlain.;Yali Cong.;Brett Doble.;Luckson Dullie.;Robin Durie.;Eric A Finkelstein.;Sam Guglani.;Melanie Hodson.;Bettina S Husebø.;Allan Kellehear.;Celia Kitzinger.;Felicia Marie Knaul.;Scott A Murray.;Julia Neuberger.;Seamus O'Mahony.;M R Rajagopal.;Sarah Russell.;Eriko Sase.;Katherine E Sleeman.;Sheldon Solomon.;Ros Taylor.;Mpho Tutu van Furth.;Katrina Wyatt.; .
来源: Lancet. 2022年399卷10327期837-884页 5828. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study.
作者: Tycho R Tromp.;Merel L Hartgers.;G Kees Hovingh.;Antonio J Vallejo-Vaz.;Kausik K Ray.;Handrean Soran.;Tomas Freiberger.;Stefano Bertolini.;Mariko Harada-Shiba.;Dirk J Blom.;Frederick J Raal.;Marina Cuchel.; .
来源: Lancet. 2022年399卷10326期719-728页
Homozygous familial hypercholesterolaemia (HoFH) is a rare inherited disorder resulting in extremely elevated low-density lipoprotein cholesterol levels and premature atherosclerotic cardiovascular disease (ASCVD). Current guidance about its management and prognosis stems from small studies, mostly from high-income countries. The objective of this study was to assess the clinical and genetic characteristics, as well as the impact, of current practice on health outcomes of HoFH patients globally.
5831. Schizophrenia.
Schizophrenia, characterised by psychotic symptoms and in many cases social and occupational decline, remains an aetiological and therapeutic challenge. Contrary to popular belief, the disorder is modestly more common in men than in women. Nor is the outcome uniformly poor. A division of symptoms into positive, negative, and disorganisation syndromes is supported by factor analysis. Catatonic symptoms are not specific to schizophrenia and so-called first rank symptoms are no longer considered diagnostically important. Cognitive impairment is now recognised as a further clinical feature of the disorder. Lateral ventricular enlargement and brain volume reductions of around 2% are established findings. Brain functional changes occur in different subregions of the frontal cortex and might ultimately be understandable in terms of disturbed interaction among large-scale brain networks. Neurochemical disturbance, involving dopamine function and glutamatergic N-methyl-D-aspartate receptor function, is supported by indirect and direct evidence. The genetic contribution to schizophrenia is now recognised to be largely polygenic. Birth and early life factors also have an important aetiological role. The mainstay of treatment remains dopamine receptor-blocking drugs; a psychological intervention, cognitive behavioural therapy, has relatively small effects on symptoms. The idea that schizophrenia is better regarded as the extreme end of a continuum of psychotic symptoms is currently influential. Other areas of debate include cannabis and childhood adversity as causative factors, whether there is progressive brain change after onset, and the long-term success of early intervention initiatives.
|